Chronic obstructive pulmonary disease (COPD) is a preventable and treatable chronic disease, but is frequently under-diagnosed and under-treated in clinical practice \[[@b1], [@b2]\]. Inhaled bronchodilators, including long-acting muscarinic antagonists (LAMAs), are the mainstay of the current management guidelines for COPD and are recognised to improve symptoms and health status \[[@b2]\].

NVA237 is a once-daily (*q.d.*) dry-powder formulation of the LAMA glycopyrronium bromide, in development for the treatment of COPD. Results from preclinical and phase II studies have demonstrated the safety and efficacy of NVA237 \[[@b3]--[@b7]\]. In a phase II study comparing the efficacy of multiple doses of NVA237 with placebo and tiotropium 18 μg *q.d*. \[[@b6]\], NVA237 50 μg *q.d.* and tiotropium showed comparable and statistically significant improvements in mean trough forced expiratory volume in 1 s (FEV~1~) *versus* placebo on days 1 and 7 (all p\<0.0001). Additionally, FEV~1~ on day 1 was significantly higher (p\<0.05) with NVA237 50 μg *versus* tiotropium from 5 min up to 2 and 4 h post-dose.

In the phase III GLycopyrronium bromide in COPD airWays clinical study 1 (GLOW1) in patients with moderate-to-severe COPD, NVA237 50 μg *q.d.* produced rapid and significant improvements in trough FEV~1~, compared with placebo, which were apparent on day 1 and sustained through week 26 \[[@b8]\]. Significant improvements were also observed over 26 weeks in dyspnoea measured by Transition Dyspnoea Index (TDI), health status measured by St George\'s Respiratory Questionnaire (SGRQ), risk of moderate-to-severe COPD exacerbations, and rescue medication use, *versus* placebo. NVA237 was well tolerated and had an acceptable safety profile, with a low incidence of typical anticholinergic adverse effects \[[@b8]\].

Tiotropium, established as a safe and effective bronchodilator, is the only licensed LAMA available currently for COPD patients and is widely used worldwide. The objective of the phase III GLOW2 study was to evaluate the efficacy and safety of NVA237 50 μg *q.d.* in patients with moderate-to-severe COPD compared with placebo and with tiotropium (as a reference comparator) over a longer treatment period of 52 weeks.

METHODS {#s2}
=======

More details are provided in the online supplement.

Patients {#s2a}
--------

Males and females ≥40 yrs of age, with a smoking history of ≥10 pack-yrs, a diagnosis of moderate-to-severe stable COPD (as defined in the 2008 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines) \[[@b9]\], post-bronchodilator FEV~1~ ≥30% and \<80% of the predicted normal, and post-bronchodilator FEV~1~/forced vital capacity (FVC) \<0.70 were enrolled.

Exclusion criteria included lower respiratory tract infection in the 6 weeks prior to screening; concomitant pulmonary disease (such as pulmonary tuberculosis or clinically significant bronchiectasis); history of asthma, malignancy of any organ system/long QT syndrome or QTc \>450 ms (males) or \>470 (females) at screening, symptomatic prostatic hyperplasia, bladder-neck obstruction, moderate/severe renal impairment, urinary retention, narrow-angle glaucoma, a known history of α~1~-antitrypsin deficiency; participation in the active phase of a supervised pulmonary rehabilitation programme; and contraindications for tiotropium or ipratropium or history of adverse reactions to inhaled anticholinergics.

Study design and treatment {#s2b}
--------------------------

This was a multicentre, double-blind, placebo-controlled with open-label tiotropium arm, parallel group study. Patients were randomised to receive NVA237 50 μg *q.d.* or placebo (both delivered *via* a low-resistance single-dose dry-powder inhaler (the Breezhaler® device; Novartis, Basel, Switzerland); 50 μg refers to the quantity of the glycopyrronium moiety present in the capsule, which corresponds to a delivered dose of 44 μg), or open-label tiotropium 18 μg (delivered *via* the HandiHaler® device; Boehringer Ingelheim, Ingelheim, Germany) in the morning between 08:00 and 11:00 h, in a ratio of 2:1:1 for a period of 52 weeks, following a washout period (of up to 7 days) and a 14-day run-in period ([fig. 1](#erj-40-05-1106-f01){ref-type="fig"}).

![GLOW2 study design.](erj-40-05-1106-f01){#erj-40-05-1106-f01}

Patients were to discontinue taking long-acting bronchodilator therapy before starting the run-in period (for at least 7 days for LAMAs or 48 h for long-acting β~2~-agonists (LABAs) or LABA/inhaled corticosteroid (ICS) combinations). Patients using LABA/ICS combinations were switched to an equivalent dose of ICS as monotherapy plus salbutamol/albuterol as rescue medication for at least 48 h prior to screening. The ICS doses had to remain stable during the screening period; patients who failed screening for this reason could be re-screened if the ICS dose had been stable for 1 month. Patients were expected to remain on the same dose of ICS throughout the study.

In addition to the study treatment, concomitant medications (inhaled or intranasal corticosteroids and H1 antagonists) were permitted in patients who had been stabilised on a recommended and constant dose prior to study entry. Patients were provided with a salbutamol/albuterol inhaler to be used as rescue medication during the study.

Efficacy assessments {#s2c}
--------------------

Efficacy was assessed in the full analysis set (FAS) which included all randomised patients who received at least one dose of the study drug; patients in the FAS were analysed according to the treatment to which they were randomised.

The primary efficacy variable was trough FEV~1~ (defined as the mean of the 23 h 15 min and the 23 h 45 min post-dose values) following 12 weeks of treatment. Key secondary variables were dyspnoea measured using the TDI at week 26 and health status according to the total score on SGRQ at week 52. Important secondary variables were time to first moderate or severe COPD exacerbation and mean daily rescue medication use over 52 weeks. Additional secondary variables included trough FEV~1~, trough FVC and inspiratory capacity at the end of day 1 and at weeks 26 and 52, serial spirometry in a subset of patients (in study sites which had the facilities and personnel for making these measurements) on day 1 and weeks 12 and 52, and the rate of COPD exacerbations in the 52-week treatment period.

Comparison of open-label tiotropium 18 μg to placebo and NVA237 in terms of all the end-points was also an additional variable; the study was not powered to show statistical superiority of NVA237 *versus* tiotropium.

Safety assessments {#s2d}
------------------

The safety population included all patients who received at least one dose of the study treatment; patients were analysed according to the treatment they received. Safety was assessed by recording treatment-emergent adverse events and monitoring vital signs (pulse rate and systolic and diastolic blood pressure), and laboratory analyses (haematology, clinical chemistry and urinalysis).

Statistics {#s2e}
----------

The primary efficacy variable (trough FEV~1~ at week 12) was analysed using a mixed model, with treatment as a fixed effect and baseline FEV~1~ and FEV~1~ reversibility (in response to 80 μg ipratopium bromide), and baseline ICS use (yes/no) acting as covariates. To reflect the randomisation scheme, the model also included baseline smoking status (current/ex-smoker) and region as fixed effects with centre nested within region as a random effect.

TDI and SGRQ scores and rescue use were analysed with the same mixed model as in the primary efficacy analysis, with baseline SGRQ score, baseline dyspnoea index and baseline rescue use replacing baseline FEV~1~ as covariates, respectively.

The time to first exacerbation was displayed for each treatment group with a Kaplan--Meier curve, and analysed using a Cox regression model, which included terms for treatment, baseline inhaled corticosteroid use (yes/no), daily total symptom score, COPD exacerbation history, FEV~1~ reversibility, smoking history and region.

RESULTS {#s3}
=======

Patient disposition and baseline characteristics {#s3a}
------------------------------------------------

A total of 1,066 patients were randomised to one of the three treatment groups in a 2:1:1 ratio (NVA237:placebo:tiotropium); 76% patients completed the study ([fig. 2](#erj-40-05-1106-f02){ref-type="fig"}). A higher percentage of patients in the placebo group discontinued (28.3%), compared with the patients in NVA237 (22.3%) and tiotropium groups (23.1%). Baseline characteristics were broadly similar between the treatment groups ([table 1](#erj-40-05-1106-t01){ref-type="table"}). A majority of the patients had moderate COPD (64%) and ∼26% of the patients had a documented history of exacerbations in the year prior to enrolment.

![Patient disposition.](erj-40-05-1106-f02){#erj-40-05-1106-f02}

###### Baseline demographics and clinical characteristics (safety population)

                                                                            NVA237 50 μg *q.d.*    Placebo     Tiotropium 18 μg *q.d.*
  ------------------------------------------------------------------------ --------------------- ------------ -------------------------
  **Subjects n**                                                                    525              268                 267
  **Age yrs**                                                                    63.5±9.1          63.6±9.1           63.9±8.2
  **Sex**                                                                                                     
   Male                                                                         339 (64.6)        173 (64.6)         168 (62.9)
   Female                                                                       186 (35.4)        95 (35.4)           99 (37.1)
  **Ethnicity**                                                                                               
   Caucasian                                                                    459 (87.4)        236 (88.1)         232 (86.9)
   Black                                                                         20 (3.8)          10 (3.7)           12 (4.5)
   Asian                                                                         26 (5.0)          12 (4.5)           15 (5.6)
   Other                                                                         20 (3.8)          10 (3.7)            8 (3.0)
  **Body mass index kg·m^−2^**                                                   27.9±6.2          27.5±6.2           27.7±6.4
  **Severity of COPD (GOLD 2008)**                                                                            
   Moderate                                                                     332 (63.2)        174 (64.9)         172 (64.4)
   Severe                                                                       187 (35.6)        92 (34.3)           94 (35.2)
   Very severe                                                                    6 (1.1)          2 (0.7)                0
  **Duration of COPD yrs**                                                        7.2±6.6          7.4±6.6             7.5±6.6
  **Baseline COPD exacerbation history^\#^**                                                                  
   0 exacerbations                                                              377 (71.8)        206 (76.9)         195 (73.0)
   1 exacerbations                                                              113 (21.5)        43 (16.0)           55 (20.6)
   ≥2 exacerbations                                                              35 (6.7)          19 (7.1)           17 (6.4)
  **ICS use at baseline**                                                       293 (55.8)        137 (51.1)         138 (51.7)
  **Smoking history**                                                                                         
   Ex-smoker                                                                    287 (54.7)        144 (53.7)         149 (55.8)
   Current smoker                                                               238 (45.3)        124 (46.3)         118 (44.2)
  **Duration of smoking pack-yrs**                                               49.0±25.4        48.0±24.0           50.2±28.0
  **Patients on different COPD medications prior to start of study^\#^**                                      
   LAMA                                                                         134 (25.5)        66 (24.6)           92 (34.5)
   LABA                                                                          58 (11.0)        38 (14.2)           25 (9.4)
   SABA                                                                         229 (43.9)        105 (39.2)         124 (46.4)
   SAMA                                                                          66 (12.6)        36 (13.4)           33 (12.4)
   ICS+LABA                                                                     194 (37.0)        88 (32.8)           97 (36.3)
   Xanthine derivatives                                                          32 (6.1)          15 (5.6)           17 (6.4)
   ICS                                                                           13 (2.5)          4 (1.5)             3 (1.1)
   Leukotriene modifiers                                                          4 (0.8)          7 (2.6)             3 (1.1)
  **Pre-bronchodilator FEV~1~ L**                                                 1.3±0.5          1.4±0.5             1.3±0.5
  **Post-bronchodilator FEV~1~ L**                                                1.5±0.5          1.5±0.5             1.5±0.5
  **Post-bronchodilator FEV~1~ % pred**                                          55.7±13.0        56.4±14.0           56.0±13.0
  **Post-bronchodilator FEV~1~ reversibility %**                                 16.2±15.2        14.6±14.5           16.4±14.5
  **Post-bronchodilator FEV~1~/FVC %**                                           50.6±10.5        50.9±10.5           50.3±10.5

Data are presented as mean±[sd]{.smallcaps} or n (%), unless otherwise stated. COPD: chronic obstructive pulmonary disease; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist; LABA: long-acting β~2~-agonist; SABA: short-acting β~2~-agonist; SAMA: short-acting muscarinic antagonist; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; FVC: forced vital capacity. Pack-yrs refers to the total years of smoking multiplied by cigarette packs smoked per day. COPD exacerbation history is the number of moderate or severe COPD exacerbations in the year prior to screening. Severity of COPD is classified based on per cent predicted FEV~1~ and FEV~1~/FVC post-bronchodilation at the screening visit. Per cent predicted FEV~1~ is obtained as a percentage of FEV~1~ relative to the predicted normal value.^\#^: \>1% of total patients.

Efficacy {#s3b}
--------

### Spirometry {#s3b1}

Least squares mean (LSM) trough FEV~1~ at week 12 (primary end-point) was significantly higher in patients receiving NVA237 50 μg *q.d.* and tiotropium 18 μg *q.d.* compared with patients receiving placebo, with a treatment difference of 97 mL (95% CI 64.6--130.2; p\<0.001) and 83 mL (95% CI 45.6--121.4; p\<0.001), respectively ([fig. 3](#erj-40-05-1106-f03){ref-type="fig"}). Trough FEV~1~ at the end of day 1 and at weeks 26 and 52 in the NVA237 group was significantly higher *versus* placebo and comparable to tiotropium ([fig. 3](#erj-40-05-1106-f03){ref-type="fig"}; [table 2](#erj-40-05-1106-t02){ref-type="table"}). At the end of day 1 and at weeks 26 and 52, compared with placebo, the treatment difference in favour of NVA237 was 91, 134 and 108 mL, respectively (all p\<0.001), while the difference in favour of tiotropium was 83, 84 and 89 mL, respectively (all p\<0.001). Furthermore, at week 26, NVA237 significantly improved trough FEV~1~ by 50 mL more than tiotropium (treatment difference: 134 *versus* 84 mL; p\<0.007). At the other time points, the improvement in trough FEV~1~ provided by NVA237 was comparable to the improvement provided by tiotropium, but the difference was not statistically significant.

![Trough forced expiratory volume in 1 s (FEV~1~) at day 1 and weeks 12, 26 and 52. Data presented as least squares mean±[se]{.smallcaps}. \*\*\*: p\<0.001 *versus* placebo; ^\#^: p=0.007 *versus* tiotropium.](erj-40-05-1106-f03){#erj-40-05-1106-f03}

###### Spirometry and symptom-related (dyspnoea, health status, rescue medication use) outcomes on day 1 and weeks 12, 26 and 52 (full analysis set population)

                                                                              Treatment difference                       
  -------------------------------------------------------------------------- ---------------------- -------------------- --------------------
  **Day 1**                                                                                                              
   Trough FEV~1~ L                                                             0.091±0.0109\*\*\*    0.083±0.0126\*\*\*      0.008±0.0110
   FEV~1~ L (5 min post-dose)                                                  0.087±0.0081\*\*\*    0.045±0.0093\*\*\*   0.041±0.0081\*\*\*
   FEV~1~ L (15 min post-dose)                                                 0.143±0.0089\*\*\*    0.078±0.0102\*\*\*   0.065±0.0089\*\*\*
   Peak FEV~1~ L                                                               0.200±0.0126\*\*\*    0.152±0.0146\*\*\*   0.047±0.0126\*\*\*
   FEV~1~ AUC~0--4\ h~                                                         0.197±0.0095\*\*\*    0.141±0.0109\*\*\*   0.056±0.0095\*\*\*
   FEV~1~ AUC~0--12\ h~                                                        0.159±0.019\*\*\*     0.127±0.0214\*\*\*      0.032±0.0189
  **Week 12**                                                                                                            
   Trough FEV~1~ L                                                             0.097±0.0167\*\*\*    0.083±0.0193\*\*\*      0.014±0.0165
   Peak FEV~1~ L                                                               0.176±0.0178\*\*\*    0.142±0.0204\*\*\*      0.033±0.0173
   FEV~1~ AUC~0--4\ h~                                                         0.176±0.017\*\*\*     0.147±0.0194\*\*\*      0.03±0.0165
   FEV~1~ AUC~0--12\ h~                                                        0.140±0.299\*\*\*      0.107±0.0337\*\*       0.034±0.0295
   FEV~1~ AUC~0--24\ h~                                                        0.106±0.0283\*\*\*      0.079±0.319\*         0.027±0.0278
   FEV~1~ AUC~12--24\ h~                                                         0.070±0.0292\*         0.047±0.0325         0.023±0.0283
   SGRQ total score                                                            -3.17±0.840\*\*\*      -2.84±0.967\*\*        -0.33±0.839
   TDI focal score                                                                0.60±0.265\*           0.26±0.303           0.34±0.257
  **Week 26**                                                                                                            
   Trough FEV~1~ L                                                             0.134±0.0189\*\*\*    0.084±0.0216\*\*\*    0.050±0.0185\*\*
   Peak FEV~1~ L                                                               0.177±0.0192\*\*\*    0.120±0.022\*\*\*     0.057±0.0189\*\*
   FEV~1~ AUC~0--4\ h~                                                         0.177±0.0182\*\*\*    0.127±0.209\*\*\*     0.05±0.0179\*\*
   SGRQ total score                                                            -3.38±0.968\*\*\*       -2.52±1.113\*         -0.86±0.964
   TDI focal score                                                               0.81±0.260\*\*        0.94±0.297\*\*        -0.13±0.253
  **Week 52**                                                                                                            
   Trough FEV~1~ L                                                             0.108±0.0195\*\*\*    0.089±0.0223\*\*\*      0.019±0.0190
   Peak FEV~1~ L                                                               0.167±0.0204\*\*\*    0.152±0.0234\*\*\*       0.014±0.02
   FEV~1~ AUC~0--4\ h~                                                         0.165±0.0198\*\*\*    0.151±0.0227\*\*\*      0.015±0.0194
   FEV~1~ AUC~0--12\ h~                                                        0.128±0.0327\*\*\*       0.06±0.0374         0.068±0.0328\*
   FEV~1~ AUC~0--24\ h~                                                        0.106±0.0322\*\*\*       0.04±0.0369         0.066±0.0322\*
   FEV~1~ AUC~12--24\ h~                                                         0.083±0.034\*          0.021±0.0389         0.062±0.0341
   SGRQ total score                                                            -3.32±1.004\*\*\*       -2.84±1.155\*         -0.48±1.002
   Change from baseline in mean daily number of puffs of rescue medication       -0.37±0.181\*        -0.63±0.209\*\*         0.25±0.181
   TDI focal score                                                                0.57±0.276\*          0.66±0.315\*         -0.08±0.269

Data are presented as least squares mean±[se]{.smallcaps}. FEV~1~: forced expiratory volume in 1 s; AUC: area under the curve; TDI: Transition Dyspnoea Index; SGRQ: St George\'s Respiratory Questionnaire. \*\*\*: p\<0.001; \*\*: p\<0.01; \*: p\<0.05.

NVA237 provided rapid bronchodilation following the first dose on day 1, with significantly higher FEV~1~ at all time points from 5 min to 4 h post-dose, compared with placebo (p\<0.001) and with tiotropium (p\<0.01; online supplement fig. S1). On day 1, the FEV~1~ LSM treatment difference for NVA237-placebo and tiotropium-placebo was 87 and 45 mL at 5 min, respectively, and 143 and 78 mL at 15 min, respectively (all p\<0.001; [table 2](#erj-40-05-1106-t02){ref-type="table"}). Peak FEV~1~ and FEV~1~ area under the curve (AUC) from 0 to 4 h (AUC~0--4\ h~) post-dose in the NVA237 group was significantly superior to placebo and tiotropium (all p\<0.001) at day 1, was significantly superior to placebo (p\<0.001) and tiotropium (p\<0.01) at week 26, and was comparable to tiotropium at weeks 12 and 52 ([table 2](#erj-40-05-1106-t02){ref-type="table"}).

The bronchodilation produced by NVA237 was sustained over the 24-h period on day 1 and weeks 12 and 52, as seen in a subpopulation of patients (the serial spirometry group; n=299). FEV~1~ AUC~0--12\ h~ with NVA237 was significantly (p\<0.001) greater than placebo at day 1 and weeks 12 and 52, significantly greater than tiotropium (p\<0.05) at week 52 and comparable to tiotropium at day 1 and week 12 ([table 2](#erj-40-05-1106-t02){ref-type="table"}). FEV~1~ AUC~0--24\ h~ with NVA237 was significantly greater (p\<0.001) than placebo at weeks 12 and 52 and significantly greater than tiotropium at week 52 (p\<0.05; [table 2](#erj-40-05-1106-t02){ref-type="table"}). Serial spirometry also demonstrated significantly higher values for FEV~1~ throughout the 24-h periods on day 1 and at weeks 12 and 52 in patients receiving NVA237, compared with placebo ([fig. 4](#erj-40-05-1106-f04){ref-type="fig"}).

![Serial spirometry on a) day 1, b) week 12 and c) week 52. a) NVA237 superior to placebo at all assessed time points (p\<0.01), superior to tiotropium at 5, 15 and 30 min, 1 and 2 h (p\<0.05). b) NVA237 *versus* placebo all time points statistically significant (p\<0.05) except 16 h, 23 h 15 min and 23 h 45 min. c) NVA237 superior to placebo at all assessed time points (p\<0.01), superior to tiotropium at 5 min,15 min and 30 min, and 1, 2 and 3 h (p\<0.05). FEV~1~: forced expiratory volume in 1 s.](erj-40-05-1106-f04){#erj-40-05-1106-f04}

Inspiratory capacity was significantly higher in the NVA237 group *versus* placebo (p\<0.001; except one pre-dose measurement at -20 min at week 52, p=0.053), and was comparable to that in the tiotropium group, at almost all evaluated time points on day 1 and weeks 12 and 52 (online supplement table S1). Trough FVC was also significantly greater in the NVA237 and tiotropium patient groups *versus* placebo at day 1 and weeks 12, 26 and 52 (p\<0.001; online supplement table S2).

### Dyspnoea {#s3b2}

NVA237 50 μg *q.d.* significantly improved the TDI focal score at week 26 (2.13) compared with placebo (1.32), with a LSM treatment difference of 0.81 (95% CI 0.299--1.320; p=0.002). This was comparable to the improvement seen in the tiotropium group *versus* placebo (LSM treatment difference: 0.94, 95% CI 0.356--1.521; p=0.002; [table 2](#erj-40-05-1106-t02){ref-type="table"}, online supplement fig. S2a). The percentage of patients achieving a minimum clinically important difference (MCID; ≥1 point improvement) \[[@b10]\] in TDI score at week 26 was significantly higher with NVA237 *versus* placebo (55.3 *versus* 44.2%; OR 1.58, 95% CI 1.118--2.245; p=0.01) and also with tiotropium *versus* placebo (53.4 *versus* 44.2%; OR 1.54, CI 1.038--2.295; p=0.032) (online supplement fig. S2b). The LSM difference in TDI focal score *versus* placebo was also significantly superior with NVA237 at weeks 12 and 52 (p=0.024 and p=0.038, respectively), and with tiotropium at week 52 (p=0.037; [table 2](#erj-40-05-1106-t02){ref-type="table"}).

### Health status {#s3b3}

SGRQ total score at week 52 was significantly improved in patients receiving NVA237 and tiotropium, with a LSM treatment difference *versus* placebo of -3.32 (95% CI -5.287-- -1.346; p\<0.001) for NVA237 and -2.84 (95% CI -5.105-- -0.571; p=0.014) for tiotropium ([table 2](#erj-40-05-1106-t02){ref-type="table"}; online supplement fig. S3). A numerically higher proportion of patients achieved the MCID in total score (≥4 point reduction) \[[@b11]\] with NVA237 (54.3%) and tiotropium (59.4%) *versus* placebo (50.8%). The LSM treatment differences in SGRQ total score for NVA237 and tiotropium *versus* placebo were also significant at weeks 12 and 26 ([table 2](#erj-40-05-1106-t02){ref-type="table"}; online supplement fig. S3).

### Exacerbations and rescue medication {#s3b4}

NVA237 50 μg *q.d.* significantly reduced the risk of exacerbations in terms of time to first moderate or severe exacerbation by 34% compared with placebo (hazard ratio (HR) 0.66, 95% CI 0.520--0.850; p=0.001; number needed to treat (NNT) 13.27) over 52 weeks ([fig. 5](#erj-40-05-1106-f05){ref-type="fig"}). NVA237 demonstrated results comparable to tiotropium which provided a 39% risk reduction *versus* placebo (HR 0.61, 95% CI 0.456--0.821; p=0.001; NNT 10.04). A 34% reduction was observed in the rate of moderate or severe COPD exacerbations in the NVA237 group compared to placebo (0.54 *versus* 0.80 per yr; rate ratio 0.66, 95% CI 0.496--0.869; p=0.003). The effect of tiotropium was not significantly different from placebo (rate ratio 0.80, 95% CI 0.586--1.105; p=0.179).

![Kaplan--Meier plot of the time to first moderate or severe chronic obstructive pulmonary disease exacerbation.](erj-40-05-1106-f05){#erj-40-05-1106-f05}

NVA237 50 μg *q.d.* and tiotropium 18 μg *q.d.* were comparable and were both superior to placebo in reducing moderate exacerbations requiring systemic corticosteroids (NVA237/placebo OR 0.61, 95% CI 0.434--0.870; p=0.006; tiotropium/placebo OR 0.62, 95% CI 0.413--0.930; p=0.021) and those requiring treatment with antibiotics (NVA237/placebo OR 0.69, 95% CI 0.495--0.957; p=0.026; tiotropium/placebo OR 0.65, 95% CI 0.438--0.949; p=0.026).

The use of rescue medication was significantly lower in patients receiving NVA237 and tiotropium *versus* those receiving placebo, with a between group treatment difference of 0.37 puffs per day (p=0.039) and 0.63 puffs per day (p=0.003), respectively ([table 2](#erj-40-05-1106-t02){ref-type="table"}).

Safety {#s3c}
------

The overall incidence of adverse events was similar across the three treatment groups (NVA237 76.6%, placebo 76.5%, tiotropium 74.2%; [table 3](#erj-40-05-1106-t03){ref-type="table"}). The most frequently reported adverse event was COPD worsening, seen with a higher frequency in the placebo group (43.3%) compared to the NVA237 and tiotropium groups (36.4 and 33.7%, respectively). Anti-muscarinic side-effects, such as dry mouth, constipation, urinary retention and urinary tract infections, occurred with a low frequency in the NVA237, placebo and tiotropium treatment groups.

###### Most frequent adverse events (≥3% in any treatment group), serious adverse events occurring in ≥3 patients in either group, deaths and discontinuations due to adverse events and electrocardiographic abnormalities

                                                   NVA237 50 μg *q.d.*    Placebo     Tiotropium 18 μg *q.d.*
  ----------------------------------------------- --------------------- ------------ -------------------------
  **Subjects n**                                           525              268                 267
  **Patients with adverse events**                     402 (76.6)        205 (76.5)         198 (74.2)
   COPD worsening^\#^                                  191 (36.4)        116 (43.3)          90 (33.7)
   Upper respiratory tract infection                    57 (10.9)        33 (12.3)           30 (11.2)
   Nasopharyngitis                                      47 (9.0)          15 (5.6)           21 (7.9)
   Sinusitis                                            28 (5.3)          14 (5.2)           10 (3.7)
   Upper respiratory tract infection, bacterial         28 (5.3)         28 (10.4)           21 (7.9)
   Back pain                                            25 (4.8)          10 (3.7)           12 (4.5)
   Headache                                             25 (4.8)          14 (5.2)           12 (4.5)
   Lower respiratory tract infection                    23 (4.4)          9 (3.4)            10 (3.7)
   Bronchitis                                           22 (4.2)          10 (3.7)           12 (4.5)
   Cough                                                21 (4.0)          13 (4.9)           12 (4.5)
   Hypertension                                         21 (4.0)          12 (4.5)           14 (5.2)
   Dry mouth                                            16 (3.0)          5 (1.9)             4 (1.5)
   Dyspnoea                                             14 (2.7)          13 (4.9)            6 (2.2)
   Pneumonia                                            14 (2.7)          12 (4.5)            7 (2.6)
   Urinary tract infection                              14 (2.7)          8 (3.0)            16 (6.0)
   Peripheral oedema                                     9 (1.7)          6 (2..2)            8 (3.0)
   Upper respiratory tract infection viral               9 (1.7)          13 (4.9)           11 (4.1)
  **Patients with serious adverse events**            66 (12.6)^¶^       43 (16.0)         41 (15.4)^¶^
   COPD worsening^\#^                                   19 (3.6)          16 (6.0)           13 (4.9)
   Pneumonia                                             7 (1.3)          7 (2.6)             4 (1.5)
   Atrial fibrillation                                   4 (0.8)             0                   0
   Dehydration                                           4 (0.8)          2 (0.7)                0
   Syncope                                               3 (0.6)          1 (0.4)                0
   Transient ischemic attack                             3 (0.6)          1 (0.4)                0
   Bronchitis                                            3 (0.6)          1 (0.4)                0
  **Deaths**                                           3 (0.6)^+^         2 (0.7)             2 (0.7)
  **Discontinuation due to adverse events**             42 (8.0)         31 (11.6)           20 (7.5)
  **Electrocardiographic abnormalities**                                             
   Total notable                                        23 (4.4)          16 (6.0)           14 (5.3)
   QTc \>500 ms                                          2 (0.4)          2 (0.7)                0
   Increase from baseline of 30--60 ms                  83 (15.8)        39 (14.6)           43 (16.2)
   Increase from baseline of \>60 ms                     1 (0.2)          1 (0.4)                0

Data are presented as n (%), unless otherwise stated. ^\#^: includes chronic obstructive pulmonary disease (COPD) exacerbation; ^¶^: includes one serious adverse event in the 30-day follow-up period; ^+^: includes one death in the 30-day follow-up period.

Serious adverse events occurred with a lower frequency in the NVA237 group, compared with the tiotropium and placebo groups ([table 3](#erj-40-05-1106-t03){ref-type="table"}). COPD exacerbation was the most common serious adverse event, occurring in 6% of placebo patients, compared to 4.9% of tiotropium and 3.6% of NVA237 patients. Atrial fibrillation (AF) occurred more frequently in the NVA237 group compared to placebo (four patients (0.8%) *versus* 0, respectively); two of the four patients had a co-existing history of AF and a third patient had a history of cardiac morbidity; none of the AF events were suspected to be related to the study medication. The percentage of patients with newly occurring or worsening clinically notable QTcF values (QT interval with Fridericia\'s correction) was low across treatment groups (NVA237 4.4%, tiotropium 5.3% and placebo 6%).

Seven deaths were reported during the treatment and the 30-day follow-up period; three in the NVA237 group (0.6%) and two each in the placebo (0.7%) and tiotropium groups (0.7%). None of the deaths was suspected to be related to the study medication.

DISCUSSION {#s4}
==========

Results from the GLOW2 study demonstrated that once-daily NVA237 50 μg is an efficacious and safe LAMA in patients with COPD over 52 weeks of treatment, and is comparable to tiotropium, the current gold standard for the treatment of COPD. Trough FEV~1~ at day 1 and at weeks 12 (primary end-point), 26 and 52 with NVA237 was significantly superior *versus* placebo. NVA237 also significantly improved dyspnoea at week 26 (mean treatment difference in TDI focal score: 0.81; p=0.002), health status at week 52 (mean treatment difference in SGRQ total score: -3.32; p\<0.001), and reduced the risk of moderate-to-severe COPD exacerbations (p=0.001) and the use of rescue medication (p=0.039), *versus* placebo. NVA237 was well tolerated, and displayed a safety profile comparable to placebo and tiotropium.

There is evidence to suggest that patients with COPD struggle to undertake morning activities; symptoms, particularly dyspnoea and activity limitation, are most challenging in the mornings \[[@b12]\]. In the GLOW2 study, NVA237 provided rapid bronchodilation following the first dose on day 1; FEV~1~ from 5 min to 4 h post-dose was significantly higher *versus* placebo at day 1 and also at weeks 12, 26 and 52 (p\<0.001), and *versus* tiotropium at day 1 and week 26 (p\<0.05). Further, the rapid bronchodilation produced by NVA237 was sustained over the 24-h period on day 1 and weeks 12, 26 and 52. A rapid onset of effect and sustained 24-h bronchodilation are important features which may have a significant positive impact on the morning routines and daily life of patients with COPD, and could potentially contribute to improving adherence to therapy.

The GOLD guidelines recognise the importance of symptom reduction in the management of COPD, and the assessment of symptom severity is a key element in the pharmacological management of COPD \[[@b2]\]. Exertional dyspnoea is one of the most distressing symptoms for patients with COPD \[[@b13]\]. Lung hyperinflation reduces inspiratory capacity, a measure that correlates with dyspnoea and exercise tolerance in patients with moderate-to-severe COPD \[[@b13]\]. In the GLOW3 study, NVA237 50 μg produced significant improvements in inspiratory capacity at isotime (defined as the last matching time point in submaximal exercise tolerance test at which for both periods the patient had a test result) at day 1, which was sustained through the study period of 3 weeks (both p\<0.001) \[[@b14]\]. This was accompanied by an immediate and significant improvement in exercise endurance from day 1, which increased over the study period (both p\<0.001). In the current GLOW2 study, the significantly greater improvement in inspiratory capacity seen with NVA237 *versus* placebo (comparable to improvement provided with tiotropium *versus* placebo) signifies a greater reduction in hyperinflation, which may contribute to a reduction in dyspnoea. Furthermore, NVA237 produced an improvement in dyspnoea on the TDI that was superior to placebo and comparable to tiotropium at weeks 12, 26 and 52. The reduced usage of rescue medication in patients receiving NVA237 compared with placebo also indicates better symptom management. This overall improvement was reflected in the SGRQ total scores which were significantly lower with NVA237 and comparable to tiotropium, *versus* placebo, at weeks 12 and 52.

COPD exacerbations reduce patients\' health status \[[@b15], [@b16]\], and increase the risk of hospitalisation and death \[[@b17], [@b18]\], and treatment costs \[[@b19]\]. Furthermore, an association has been reported between frequency of exacerbations and increased rate of lung function decline \[[@b20], [@b21]\]. Hence, prevention of exacerbations and reduction of future risk should be a consideration in the management of COPD \[[@b2]\]. In the GLOW2 study, NVA237 reduced the risk of moderate-to-severe COPD exacerbations in patients with COPD by 34% *versus* placebo. The NNT to avoid one moderate-to-severe exacerbation in patients with COPD over 52 weeks with NVA237 *versus* placebo was 13.27; it was comparable to the NNT with tiotropium *versus* placebo (10.04). It is noteworthy that in the GLOW2 study, a majority of the patients (\>63%) had moderate COPD, and only a minority (27%) had a baseline history of exacerbations. This makes the improvement seen in COPD exacerbations more significant, since it might indicate that the beneficial effects of NVA237 on exacerbations could apply across a broad COPD population, not just patients with severe COPD or a history of frequent exacerbations. It should be noted that the GLOW2 study was not powered to analyse the rate of exacerbations and the study population was not enriched by recruiting patients with frequent exacerbations. Also, the lower baseline exacerbation history in patients in the GLOW2 study compared with the ECLIPSE study, in which 39% of patients with moderate COPD and 52% of those with severe COPD had one or more exacerbations during the past year \[[@b22]\], could potentially be due to different criteria used for defining exacerbations in the two studies; in the GLOW2 study pre-defined criteria needed to be met for an event to be classified as an exacerbation, while the ECLIPSE study had no such criteria.

The safety profile of NVA237 50 μg *q.d.* observed in the current study was consistent with the known safety profile of NVA237 and was comparable to the safety profile of tiotropium. Anti-muscarinic side-effects, such as dry mouth, constipation, urinary retention and urinary tract infections, occurred with a low frequency in all treatment groups. Overall, NVA237 50 μg *q.d.* was generally well tolerated over a longer treatment period of 52 weeks.

Tiotropium, being the only once-daily LAMA currently available for COPD, was an appropriate control for the GLOW2 study since it provides a degree of validation for characterisation to a well-studied bronchodilator. However, technical difficulties make it difficult to blind tiotropium in clinical trials: tiotropium is a hygroscopic powder that cannot be removed from the commercial capsules (marked with a logo) for repackaging into unmarked capsules. A potential limitation of the GLOW2 study was the inability to blind tiotropium treatment, raising the possibility of bias in comparing the results for NVA237 with those of tiotropium.

In open-label study designs, there is a possibility that patients on unblinded active drugs may report more favourable outcomes because they expect a benefit; previous experience with the unblinded comparator may also affect their reporting of subjective efficacy end-points or adverse effects. In the GLOW2 study, the open-label nature of the comparison with tiotropium could have mildly influenced the results of the patient-reported outcomes or rescue medication usage. However, the primary and the majority of the secondary efficacy objectives in the GLOW2 study were based on spirometric end-points, with comparable results seen in the NVA237 and the tiotropium treatment groups, including serial spirometry in a subpopulation of patients, which demonstrated comparable efficacy profiles for NVA237 and tiotropium at week 12. Spirometry is considered to be an objective, standardised and reproducible measure of airflow limitation, and is not likely to be subject to bias. Furthermore, the results obtained in the GLOW2 study for tiotropium *versus* placebo in terms of improvements in lung-function, TDI and SGRQ scores were consistent with results from other randomised placebo-controlled trials using blinded tiotropium \[[@b23]--[@b30]\].

It may be pointed out that although the magnitude of improvement observed in trough FEV~1~ with tiotropium *versus* placebo was comparable to the improvement seen with tiotropium in recent randomised tiotropium trials \[[@b23]--[@b26]\], it was lower than the improvement observed in earlier such studies \[[@b27]--[@b29]\]. Some of the possible explanations could include differences in baseline demographics of patient population, shift in the baseline characteristics of patients entering trials due to benefits obtained from the variety of short- and long-acting bronchodilators currently available, as opposed to the limited options available previously, and selective recruitment due to the impact of concomitant medications permitted \[[@b31]\].

The results for NVA237 50 μg *q.d.* *versus* placebo in the GLOW2 study were comparable to those for tiotropium, suggesting that NVA237 50 μg *q.d.* has the potential to be a useful alternative to tiotropium.

Conclusions {#s4a}
-----------

The results from the GLOW2 study demonstrated that over 52 weeks, once-daily NVA237 50 μg has a rapid onset of action and sustained 24-h efficacy, and is safe and well tolerated. Once-daily NVA237 provided comparable efficacy to tiotropium, the current gold standard for the treatment of COPD, and could be an alternative LAMA choice for patients with COPD.
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